Abstract
Nested Therapeutics has launched with $90 million in series A funding to develop small-molecule cancer medicines by identifying druggable pockets on proteins involved in cancer-relevant pathways. The company’s lead compound, NEST-1, is a molecular glue that targets the proteins involved in the MAPK cellular signaling pathway. One scientific cofounder is Kevan Shokat, a University of California, Berkeley, chemistry professor who first drugged the protein KRas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
